1. Academic Validation
  2. Effect of trapidil on effector functions of monocytes related to atherosclerotic plaque

Effect of trapidil on effector functions of monocytes related to atherosclerotic plaque

  • Eur J Pharmacol. 2001 Oct 12;428(3):371-9. doi: 10.1016/s0014-2999(01)01336-x.
Y Kato 1 T Tsuda Y Hosaka T Takahashi K Shirakawa S Furusako K Mizuguchi H Mochizuki
Affiliations

Affiliation

  • 1 Research Center, Mochida Pharmaceutical Co., Ltd., 722 Jimba-aza-Uenohara, Gotemba, 412-8524, Shizuoka, Japan. [email protected]
Abstract

The infiltration and activation of inflammatory cells play an important role in the formation and stability of coronary atherosclerotic plaque in patients with acute coronary syndrome. In this study, we evaluated the effect of trapidil, an anti-platelet agent, on atheroma-related functions of human T cells and monocytes. Trapidil and anti-CD154 (CD40 ligand) antibody inhibited the increase of procoagulant activity in the mixed lymphocyte reaction; trapidil also suppressed the induction of tissue factor, monocyte chemoattractant protein-1 (MCP-1) and matrix metalloproteinase-9 in the mixed lymphocyte reaction. Trapidil did not alter CD154 expression on isolated T cells, but it diminished CD40 expression on isolated monocytes and human monocytic leukemia THP-1 cells stimulated with interferon-gamma. Moreover, trapidil reduced MCP-1 production of isolated monocytes and THP-1 cells stimulated with interferon-gamma plus CD154-transfected cells. This effect was not seen with Other tested anti-platelet agents and coronary vasodilators. In conclusion, trapidil directly acts on monocytes/macrophages to lower their susceptibility to CD154 on T cells.

Figures
Products